NRD
OCUL icon

Nebula Research & Development’s Ocular Therapeutix OCUL Stock Holding History

Nebula Research & Development’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,777
Closed -$112K – 617
2023
Q2 		$112K Sell
21,777
-697
-3% -$4.14K 0.09% 295
2023
Q1 		$118K Buy
+22,474
New +$107K 0.21% 195

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nebula Research & Development's OCUL Position: Q3 2023 in Review

Nebula Research & Development sold out of Ocular Therapeutix (OCUL) in Q3 2023, closing a stake of 21,777 shares — an estimated $112K sold.

Nebula Research & Development first reported a position in OCUL in Q1 2023 and held it in 2 quarters. The position peaked at $118K in Q1 2023. 113 funds tracked by Wall St. Rank hold OCUL as of Q3 2023.

  • Nebula Research & Development reported no remaining Ocular Therapeutix position as of Q3 2023 after selling out during the quarter.
  • Nebula Research & Development sold 21,777 Ocular Therapeutix shares in Q3 2023, an estimated $112K.
  • Nebula Research & Development first reported a position in Ocular Therapeutix in Q1 2023 and held it in 2 quarters.
  • Nebula Research & Development's Ocular Therapeutix position peaked at $118K in Q1 2023.
  • 113 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2023.

Based on Nebula Research & Development's 13F filing for Q3 2023, filed 14 Nov 2023.